(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

INVENTIA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

INVENTIA

ST13

US500000079385808

Classe

7, 9, 10, 35, 42

Pedido

79385808

Registro

8105499

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

45

Atualização mais recente

23/07/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

7, 9, 10, 35, 42

Data de depósito

14/07/2023

Data de registro

20/01/2026

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

20/01/2026

Última transação

23/07/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

AU

Examinador

YOUNG, CARRIE SKYE

Localização atual

Historical data usage

Titulares e representantes

Titulares

Inventia Pty Ltd

Representantes

Robyn S. Lederman Brooks Kushman PC

Classificação técnica

Classes Nice

Classe 7Classe 9Classe 10Classe 35Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 7

3D printers; computerized printers for the generation of 3D shaped parts; machines, namely, 3D bioprinters for the printing of living cells and tissues or printing 3D cell structures; cartridges being parts of 3D printers for containing printing materials; cartridges being parts of 3D printers for containing bioprinting materials; printing cartridges being parts of 3D printers for containing biomaterials and reagents; printing cartridges being parts of 3D printers for containing bio-ink; robotic handling apparatus, namely, robotic handling apparatus and arms for industrial and commercial use; accessories and spare parts for three dimensional (3D) printers for the production of biological materials, namely, print heads for three dimensional (3D) printers; machines, namely, three dimensional (3D) printer for the printing of engineered living tissues; three dimensional (3D) printers; structural parts and fittings therefor * ; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases *

Classe 9

Laboratory robots; downloadable software for monitoring and controlling communication between computers and automated machine systems; downloadable software for operating and controlling 3D printers; downloadable operating software to control laboratory apparatus for fabrication of three dimensional (3D) engineered living tissues; downloadable software for the purpose of the manufacture of products by means of a 3D printer, including medical products; laboratory instruments and apparatus, namely, cell assembly apparatus for laboratory use for fabrication of three dimensional (3D) engineered living tissues; print heads for 3D printers and bioprinters; downloadable electronic publications, namely, pamphlets, brochures, journals, books, manuals, newsletters and booklets in the field of living tissue, tissue regeneration, 3D printing, cell printing, cell assembly and biomedical research; parts and fittings for all of the foregoing, namely, electronic control panels with digital displays for the control of three dimensional (3D) printers, printer cables, and ink cartridges, unfilled, for printers * ; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases *

Classe 10

Surgical robots, namely, robotic apparatus for medical or surgical purposes; surgical robots; surgical robots for medical purposes; medical apparatus for use in soft tissue repair, reconstruction of soft tissue deficiencies, regenerative surgery, plastic reconstructive surgery and wound healing in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research; structural parts and fittings therefor; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders, obesity, diabetes, severe dyslipidemias, NASH, inflammatory diseases and autoimmune diseases

Classe 35

Data management; wholesale and retail store services for pharmaceutical, medical, scientific, laboratory and 3D printing consumables and supplies; online wholesale and retail store services featuring pharmaceutical, medical, scientific, laboratory and 3D printing consumables and supplies; administrative processing of purchase orders; order fulfillment services, namely, computerised stock ordering and purchasing; computerised data processing; compiling and analyzing statistics, data and other sources of scientific information for business purposes; computerised register management, namely, maintenance of registers for others * none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases *

Classe 42

Scientific and technological services and research and design relating thereto, all in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research; industrial analysis, industrial research and industrial design services, all in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research; design and development of computer software; software as a service (SAAS) services, namely, hosting software for use by others in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research and to identify, select and print biomaterials for the purpose of experiments; providing online non-downloadable software for use by others in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research and to identify, select and print biomaterials for the purpose of experiments; computer support services, namely, computer programming and software installation, repair and maintenance services; scientific research services, specifically, analysis of statistical data for scientific research purposes; design of software; design and development of new products in the field of biological materials; visual design services in the nature of designing visual elements for print media; new product design services; scientific research relating to design in the field of 3D printing, bioprinting, cell printing, cell assembly and biomedical research; laboratory research in the field of biomedical research, bioprinting, cell printing, cell assembly and the creation and engineering of 3D cells and living tissues; biomedical research; cloud computing featuring software for use in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research and to identify, select and print biomaterials for the purpose of experiments; technical consultancy in the field of scientific research; scientific research in the field of soft tissue repair, reconstruction of soft tissue deficiencies, regenerative surgery, plastic reconstructive surgery, wound healing, drug discovery, genetics, dermatology and oncology; scientific research into the development of new products; technical support services, namely, troubleshooting in the nature of repair of medical equipment and diagnostic laboratory instruments and systems; providing online non-downloadable web-based computer software platforms for laboratory and diagnostic equipment information management, monitoring and analysis; providing information and online information regarding the foregoing; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases

Publicações

Histórico de despachos e eventos da marca no USPTO.

45 publicações encontradas

FICS

FINAL DISPOSITION NOTICE SENT TO IB

23/07/2026

FIMP

FINAL DISPOSITION PROCESSED

23/07/2026

NURC

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED

07/07/2026

LIME

LIMITATION FROM THE IB EXAMINED AND ENTERED

17/06/2026

COC.

CORRECTION UNDER SECTION 7 - PROCESSED

17/06/2026

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

17/06/2026

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

20/04/2026

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

20/01/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

20/01/2026

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

25/12/2025

GPNX

NOTIFICATION PROCESSED BY IB

11/12/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/12/2025

PUBO

PUBLISHED FOR OPPOSITION

02/12/2025

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

26/11/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

26/11/2025

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

25/11/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

31/10/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

27/10/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

27/10/2025

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

27/10/2025

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

06/06/2025

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

23/05/2025

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

22/05/2025

GNFR

FINAL REFUSAL E-MAILED

22/05/2025

CNFR

FINAL REFUSAL WRITTEN

22/05/2025

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

20/05/2025

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

20/05/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

15/04/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

15/04/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

15/04/2025

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

28/03/2025

RFNT

REFUSAL PROCESSED BY IB

23/11/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

04/11/2024

RFRR

REFUSAL PROCESSED BY MPU

04/11/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

30/10/2024

CNRT

NON-FINAL ACTION WRITTEN

29/10/2024

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

22/10/2024

NREP

NEW REPRESENTATIVE AT IB RECEIVED

30/08/2024

NREP

NEW REPRESENTATIVE AT IB RECEIVED

23/08/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

24/03/2024

CNRT

NON-FINAL ACTION WRITTEN

23/03/2024

DOCK

ASSIGNED TO EXAMINER

22/03/2024

MAFR

APPLICATION FILING RECEIPT MAILED

26/12/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

22/12/2023

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

21/12/2023

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace INVENTIA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.